Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection
NCT04164212Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2020
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of live attenuated influenza vaccine in influenza, sponsored by University of Alabama at Birmingham. Primary endpoints: Influenza virus replication at day 2 and Markers of inflammation at day 2. Started Sep 2020; status: completed.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04164212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164212.